曲妥珠单抗美登素(T-DM1)在HER2阳性晚期乳腺癌患者中的安全性:KAMILLA研究队列1的主要结果
KAMILLA是一项单臂、开放标签、国际性IIIb期安全性研究,评估T-DM1在既往接受过治疗的HER2阳性晚期乳腺癌患者中的安全性。2002例接受治疗患者中,不良事件发生率为93.0%,严重不良事件为21.3%,≥3级不良事件为37.5%。中位无进展生存期为6.9个月,中位总生存期为27.2个月。
要点
- 2002例接受T-DM1治疗的患者中,不良事件发生率为93.0%,严重不良事件为21.3%。
- ≥3级不良事件发生率为37.5%,最常见为贫血(3.0%)、血小板减少症(2.7%)和疲乏(2.5%)。
- 中位无进展生存期为6.9个月(95%CI 6.0-7.6),中位总生存期为27.2个月(95%CI 25.5-28.7)。
核心结论
- KAMILLA是迄今为止研究T-DM1治疗患者的最大队列,结果与既往随机研究一致,支持T-DM1是既往接受过治疗的HER2阳性晚期乳腺癌患者安全、可耐受且有效的治疗。
研究设计与样本
- KAMILLA(NCT01702571)是一项单臂、开放标签、国际性IIIb期安全性研究,纳入既往接受过化疗和HER2靶向药物治疗后出现进展的HER2阳性晚期乳腺癌患者。
- 患者接受T-DM1 3.6 mg/kg每3周一次,直至出现不可接受的毒性、退出或疾病进展。
- 共2002例患者接受治疗,中位年龄55岁(范围26-88岁),373例(18.6%)年龄≥65岁。
主要发现
- 1321例(66.0%)接受过≥2线既往转移性治疗,398例(19.9%)有基线中枢神经系统转移。
- 不良事件和严重不良事件分别发生于1862例(93.0%)和427例(21.3%)患者。
- ≥3级不良事件发生于751例(37.5%)患者,最常见的三种(按监管活动医学词典各术语)为贫血(3.0%)、血小板减少症(2.7%)和疲乏(2.5%)。
- 中位无进展生存期为6.9个月(95%CI 6.0-7.6),中位总生存期为27.2个月(95%CI 25.5-28.7)。
- 随着既往晚期治疗线数增加(0-1线 vs 4线及以上),中位无进展生存期从8.3个月数值下降至5.6个月,中位总生存期从31.3个月数值下降至22.5个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) are candidates for trastuzumab emtansine (T-DM1) treatment sometime in their disease history. KAMILLA evaluated safety of T-DM1 in patients with previously treated HER2-positive locally advanced or metastatic BC (advanced BC). METHODS: KAMILLA (NCT01702571) is a single-arm, open-label, international, phase IIIb safety study of patients with HER2-positive advanced BC with progression after prior treatment with chemotherapy and a HER2-directed agent for MBC or within 6 months of completing adjuvant therapy. Patients received T-DM1 (3.6 mg/kg every 3 weeks) until unacceptable toxicity, withdrawal or disease progression. RESULTS: Among 2002 treated patients, median age was 55 years (range, 26-88; 373 [18.6%] aged ≥65 years), 1321 (66.0%) received ≥2 prior metastatic treatment lines and 398 (19.9%) had baseline central nervous system metastases. Adverse events (AEs) and serious AEs occurred in 1862 (93.0%) and 427 (21.3%) patients, respectively. Grade ≥3 AEs occurred in 751 (37.5%) patients; the three most common (individual Medical Dictionary for Regulatory Activity terms) were anaemia (3.0%), thrombocytopaenia (2.7%) and fatigue (2.5%). Median progression-free survival (PFS) was 6.9 months (95% confidence interval [CI], 6.0-7.6). Median overall survival (OS) was 27.2 months (95% CI, 25.5-28.7). With increasing lines of prior advanced therapy (0-1 versus 4+), median PFS and OS decreased numerically from 8.3 to 5.6 months and from 31.3 to 22.5 months, respectively. CONCLUSIONS: KAMILLA is the largest cohort of T-DM1-treated patients studied to date. Results are consistent with prior randomised studies, thereby supporting T-DM1 as safe, tolerable and efficacious treatment for patients with previously treated HER2-positive advanced BC.
引用
- Montemurro F, Ellis P, Anton A, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019. PMID: 30708264. doi:10.1016/j.ejca.2018.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。